MiniMed Group (MMED) SEC filings document the regulatory record of a Nasdaq-listed diabetes technology company focused on insulin delivery systems, CGMs, sensors, algorithms, and app-connected diabetes management. MiniMed's filings include annual reports, quarterly reports, proxy statements, and Form 8-K material event reports.
For MMED, the most relevant filings often relate to medical device operations and newly public company governance. Annual reports and 10-Q filings can describe business structure, risk factors, capital structure, financial results, clinical and regulatory matters, and disclosures tied to MiniMed's separation from Medtronic. Form 8-K filings have covered financial results, board appointments, executive compensation plans, officer departures, cybersecurity-related disclosures, and other material events.
Proxy statements are useful for reviewing director elections, auditor ratification, advisory compensation votes, and governance matters. Form 4 insider transaction filings can show reported purchases, sales, or equity awards by directors and officers when such filings are submitted. 10-K and 10-Q reports are especially important for understanding how MiniMed reports its diabetes technology business after becoming a public company.
AI-powered summaries can translate dense filing language into plain-English explanations, while real-time EDGAR updates can surface new MMED filings as they are released. These summaries are most useful when reviewing long annual reports, quarterly updates, proxy statements, and insider transaction disclosures.
MiniMed Group, Inc. director Kevin E. Lofton reported an equity compensation grant of 27,778 shares of Common Stock in the form of restricted stock units. The award was granted at no cash cost per share and is scheduled to vest on the one-year anniversary of the grant date.
After this grant, Lofton is shown as owning 27,778 shares directly, which include shares to be issued upon future vesting of one or more restricted stock units. This filing reflects a routine compensation-related acquisition rather than an open-market purchase or sale.
MiniMed Group, Inc. officer John Gyurci reported equity compensation grants on March 9, 2026. He received 2,778 performance-based restricted stock units, each tied to one share of common stock, which vest on March 9, 2027 only if MMED’s closing price reaches at least $32.05 as of the Divestment Date defined in a March 1, 2026 separation agreement. He was also granted options on 25,253 shares of common stock at an exercise price of $18.00 per share, expiring on March 9, 2036, vesting 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030.
MiniMed Group, Inc. officer Chandrasena Gillian reported compensation-related equity awards, not open-market trades. She received 6,945 performance-based restricted stock units, each representing a right to one MMED common share, which vest on March 9, 2027 if MMED’s closing share price is at least $32.05 as of the defined Divestment Date.
She also received employee stock options for 63,132 MMED common shares at an exercise price of $18.00 per share, expiring in 2036. These options vest 33% on March 9, 2028, 33% on March 9, 2029, and 34% on March 9, 2030. All holdings reported are owned directly.
MiniMed Group, Inc. insider Courtney Nelson received new equity awards as compensation. On March 9, 2026, Nelson was granted 6,945 performance-based restricted stock units, each tied to one share of MMED common stock. These units vest on March 9, 2027 if MMED’s closing share price reaches at least $32.05 as of the Divestment Date defined in a March 1, 2026 separation agreement.
On the same date, Nelson also received an option to purchase 63,132 shares of MMED common stock at an exercise price of $18.00 per share, expiring March 9, 2036. This option vests 33% on March 9, 2028, 33% on March 9, 2029, and 34% on March 9, 2030. All awards are reported as directly owned and are grants, not open-market purchases or sales.
MiniMed Group, Inc. reported that officer Ali Dianaty received equity-based compensation. On March 9, 2026, Dianaty was granted 13,889 performance-based RSUs, each tied to one share of MMED common stock and vesting around March 9, 2027 based on share-price performance and a divestment-related date defined in a March 1, 2026 separation agreement. On the same date, Dianaty also received 126,263 stock options with a $18.00 exercise price, expiring in 2036, vesting 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030. All holdings reported are direct and reflect compensation grants rather than open-market purchases or sales.
MiniMed Group, Inc. reported that EVP and Chief Financial Officer Chad Spooner received new equity awards. He was granted 27,778 performance-based restricted stock units, each representing one share of common stock, vesting on March 9, 2027, if MiniMed’s share price reaches at least $32.05 as of the Divestment Date. He also received options for 84,176 shares of common stock at an exercise price of $18.00 per share, vesting 33% on March 9, 2028, 33% on March 9, 2029, and 34% on March 9, 2030, with expiration on March 9, 2036.
MiniMed Group, Inc. Chief Executive Officer Dallara Que reported awards of new equity-based compensation. On March 9, 2026, Que received 83,334 performance-based restricted stock units, each representing a contingent right to one share of MiniMed common stock. These units vest on March 9, 2027 if MiniMed’s common stock closes at or above $32.05 per share as of the defined Divestment Date.
On the same date, Que also received 252,526 employee stock options with an exercise price of $18.00 per share and expiration on March 9, 2036. These options vest in tranches of 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030, providing a long-term incentive structure tied to future service and share price performance.
MiniMed Group, Inc. completed its initial public offering of 28,000,000 shares of common stock at $20.00 per share, generating net proceeds of approximately $538 million. The company retained $309 million, resulting in approximately $350 million of cash on hand, and used the remainder to repay intercompany debt owed to Medtronic.
MiniMed was separated from Medtronic’s Diabetes business, with Medtronic now owning approximately 90.03% of outstanding shares. The company established a $500 million five-year senior secured revolving credit facility for working capital and general corporate purposes, reconstituted its board and committees, and adopted new equity, incentive, deferred compensation, and retirement plans for directors and executives.
MiniMed Group, Inc. director Brett A. Wall filed an initial Form 3 to report his status as an insider of the company. The filing does not list any reportable transactions or derivative positions, indicating that this document serves primarily as a baseline ownership and affiliation disclosure.
MiniMed Group, Inc. filed an initial ownership report for director Walter Matthew R. This Form 3 filing for ticker MMED identifies him as a director of the company. The filing does not report any specific stock transactions or holdings, serving only as a baseline disclosure of insider status.